A randomized, double-blind, pivotal trial of eganelisib in combination with chemotherapy for mTNBC patients
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Eganelisib (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MARIO-4
- Sponsors Infinity Pharmaceuticals
Most Recent Events
- 12 Jan 2022 New trial record
- 05 Jan 2022 According to an Infinity Pharmaceuticals media release, the company will finalize MARIO-4 design soon.
- 05 Jan 2022 According to an Infinity Pharmaceuticals media release, the Company expects to initiate this trial by the end of 2022.